The biotech resurrection continues

The biotech resurrection continues

Source: 
EP Vantage
snippet: 

One of the benefits of biotech being a risky sector is that the highs are sometimes bigger than the lows – think Vanda or Amarin’s phoenix-like rises from the dead. Yesterday Lexicon and DBV Technologies joined Trillium in reminding investors that you should never write any biotech company off completely.

Unlike Trillium, however, which climbed 278% in 2020 on lots of sentiment and a small investment from Pfizer, Lexicon and DBV revealed positive regulatory updates on lead assets, Zynquista and Viaskin Peanut respectively. The markets had largely given up on both projects, which might now have a future after all.